ATE406387T1 - Verfahren zur herstellung von hydroxyalkylstärkederivaten - Google Patents

Verfahren zur herstellung von hydroxyalkylstärkederivaten

Info

Publication number
ATE406387T1
ATE406387T1 AT03020424T AT03020424T ATE406387T1 AT E406387 T1 ATE406387 T1 AT E406387T1 AT 03020424 T AT03020424 T AT 03020424T AT 03020424 T AT03020424 T AT 03020424T AT E406387 T1 ATE406387 T1 AT E406387T1
Authority
AT
Austria
Prior art keywords
starch derivatives
hydroxyalkyl starch
producing hydroxyalkyl
producing
derivatives
Prior art date
Application number
AT03020424T
Other languages
English (en)
Inventor
Norbert Zander
Original Assignee
Fresenius Kabi De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31995520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE406387(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02020425A external-priority patent/EP1400533A1/de
Application filed by Fresenius Kabi De Gmbh filed Critical Fresenius Kabi De Gmbh
Application granted granted Critical
Publication of ATE406387T1 publication Critical patent/ATE406387T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C08B31/10—Alkyl or cycloalkyl ethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C08B31/12—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/003—Crosslinking of starch
    • C08B31/006—Crosslinking of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/18—Oxidised starch
    • C08B31/185—Derivatives of oxidised starch, e.g. crosslinked oxidised starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03020424T 2002-09-11 2003-09-11 Verfahren zur herstellung von hydroxyalkylstärkederivaten ATE406387T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40978102P 2002-09-11 2002-09-11
EP02020425A EP1400533A1 (de) 2002-09-11 2002-09-11 Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
PCT/EP2003/008829 WO2004024776A1 (en) 2002-09-11 2003-08-08 Method of producing hydroxyalkyl starch derivatives

Publications (1)

Publication Number Publication Date
ATE406387T1 true ATE406387T1 (de) 2008-09-15

Family

ID=31995520

Family Applications (3)

Application Number Title Priority Date Filing Date
AT03020423T ATE323723T1 (de) 2002-09-11 2003-09-11 Hasylierte polypeptide, besonders hasyliertes erythropoietin
AT03020424T ATE406387T1 (de) 2002-09-11 2003-09-11 Verfahren zur herstellung von hydroxyalkylstärkederivaten
AT03020425T ATE449112T1 (de) 2002-09-11 2003-09-11 Hydroxyalkylstärke-derivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03020423T ATE323723T1 (de) 2002-09-11 2003-09-11 Hasylierte polypeptide, besonders hasyliertes erythropoietin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03020425T ATE449112T1 (de) 2002-09-11 2003-09-11 Hydroxyalkylstärke-derivate

Country Status (24)

Country Link
US (5) US20050238723A1 (de)
EP (8) EP1398327B1 (de)
JP (4) JP2006516534A (de)
KR (3) KR101045422B1 (de)
CN (2) CN1681844A (de)
AR (3) AR041097A1 (de)
AT (3) ATE323723T1 (de)
AU (6) AU2003260393B2 (de)
BR (3) BR0314106A (de)
CA (2) CA2496317C (de)
CY (1) CY1109813T1 (de)
DE (7) DE20321836U1 (de)
DK (3) DK1398328T3 (de)
ES (4) ES2399006T3 (de)
IL (5) IL166506A0 (de)
MX (4) MXPA05002594A (de)
NO (2) NO20051427L (de)
PL (3) PL217085B1 (de)
PT (3) PT1398322E (de)
RU (3) RU2326891C2 (de)
SI (2) SI1398327T1 (de)
TW (1) TW200418875A (de)
WO (3) WO2004024761A1 (de)
ZA (1) ZA200600651B (de)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
AU2003260393B2 (en) * 2002-09-11 2009-10-01 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
DE02020425T1 (de) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
DE60323756D1 (de) 2002-10-08 2008-11-06 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
DE10256558A1 (de) * 2002-12-04 2004-09-16 Supramol Parenteral Colloids Gmbh Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
US20080206182A1 (en) * 2003-08-08 2008-08-28 Fresenius Kabi Deutschland Gmbh Conjugates of a Polymer and a Protein Linked by an Oxime Group
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
HRP20110056T1 (hr) * 2003-08-08 2011-02-28 Fresenius Kabi Deutschland Gmbh Konjugati hidroksialkil škroba i g-csf
KR101154343B1 (ko) * 2003-08-08 2012-07-05 프레제니우스 카비 도이치란트 게엠베하 히드록시알킬 스타치 및 ｇ-ｃｓｆ의 컨쥬게이트
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
AR048035A1 (es) * 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
EP2279752A3 (de) * 2004-03-11 2011-08-24 Fresenius Kabi Deutschland GmbH Konjugate von hydroxyalkylstärke und einem protein hergestellt durch native chemische ligation
EP1758608A2 (de) * 2004-03-11 2007-03-07 Fresenius Kabi Deutschland GmbH Konjugate von hydroxyalkylstärke und erythropoetin
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
WO2006094826A2 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Method for coupling enzymatically activated glycoconjugates to a hydroxyalkyl starch
EP1861124A2 (de) * 2005-03-11 2007-12-05 Fresenius Kabi Deutschland GmbH Herstellung von bioaktiven glykoproteinen aus inaktiven ausgangsmaterialien durch konjugation mit hydroxyalkylstärke
EP1762250A1 (de) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
US8470963B2 (en) 2006-06-30 2013-06-25 Sku Asset Management Gmbh Multifunctional compounds for pharmaceutical purposes
CN101511391B (zh) * 2006-07-25 2013-03-13 利普生技术有限公司 N末端聚唾液酸化
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
CN103804489A (zh) * 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
DK2121713T3 (da) 2007-01-18 2013-06-24 Genzyme Corp Oligosaccharider, omfattende en aminooxygruppe, og konjugater deraf
CN101485897B (zh) 2008-01-14 2015-05-20 纪欣 生物相容性止血、防粘连、促愈合、外科封闭的变性淀粉材料
WO2009043049A2 (en) 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
ES2962777T3 (es) 2007-11-15 2024-03-21 Amgen Inc Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
EP2070951A1 (de) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Verfahren zur Herstellung eines Hydroxyalkylstärkederivats mit zwei Linkern
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
JP2011518940A (ja) * 2008-04-28 2011-06-30 サーモディクス，インコーポレイティド ヒドラジド架橋を有するポリ−α（１→４）グルコピラノース−ベースのマトリクス
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2166085A1 (de) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalente modifizierte Zellen
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
US8680263B2 (en) * 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
CA3019967A1 (en) 2008-11-13 2010-05-20 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of bmp-6
RU2519225C2 (ru) 2008-12-06 2014-06-10 Б. Браун Мельзунген Аг Опосредующие транспорт коллоидные лекарственные соединения
WO2010099003A2 (en) 2009-02-26 2010-09-02 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US9018372B2 (en) 2009-03-31 2015-04-28 B. Braun Melsungen Ag Bonding products of aminated polysaccharides
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
KR101759300B1 (ko) 2009-07-27 2017-07-31 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
KR101912335B1 (ko) * 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
PT2575935E (pt) 2010-06-07 2015-10-20 Amgen Inc Dispositivo de administração de medicamento
US20130178437A1 (en) * 2010-07-09 2013-07-11 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
AU2011276120B2 (en) * 2010-07-09 2013-12-19 Azim Abul Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
US20130217871A1 (en) * 2010-07-09 2013-08-22 Helmut Knoller Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
US20140073602A9 (en) 2010-07-09 2014-03-13 Fresenius Kabi Deutschland Gmbh Nitric oxide delivering hydroxyalkyl starch derivatives
PL2598172T3 (pl) 2010-07-30 2019-09-30 Baxalta GmbH Katalizatory nukleofilowe do wiązania oksymowego
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
EP2691065B1 (de) 2011-03-31 2017-03-01 Amgen Inc. Fläschchenadapter und system damit
US10092706B2 (en) 2011-04-20 2018-10-09 Amgen Inc. Autoinjector apparatus
US20120329127A1 (en) 2011-05-27 2012-12-27 Baxter Healthcare S.A. Therapeutic proteins with increased half-life and methods of preparing same
US20150044714A1 (en) * 2011-06-07 2015-02-12 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine sPLA2 MONITORING STRIP
WO2013021056A1 (en) 2011-08-10 2013-02-14 Ludwig-Maximilians-Universität München Method for the controlled intracellular delivery of nucleic acids
PL3045187T3 (pl) 2011-10-14 2019-09-30 Amgen Inc. Wstrzykiwacz i sposób montażu
WO2013113503A1 (en) 2012-01-31 2013-08-08 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and an oligonucleotide
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
EP2926829B1 (de) * 2012-11-30 2018-07-25 Glytech, Inc. An zuckerkette angehängter linker, verbindung mit an zuckerkette angehängtem linker und physiologisch aktiver stoff oder salz davon und verfahren zur herstellung davon
CN110041427B (zh) 2013-03-15 2023-05-23 本质生命科学有限公司 抗铁调素抗体及其用途
SG11201507417RA (en) 2013-03-15 2015-10-29 Amgen Inc Body contour adaptable autoinjector device
CA2904661C (en) 2013-03-15 2022-03-15 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
TWI580451B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
US20160311933A1 (en) * 2013-03-20 2016-10-27 Fresenius Kabi Deutschland Gmbh Process for the preparation of thiol functionalized hydroxyalkyl starch derivatives
WO2014147173A1 (en) * 2013-03-20 2014-09-25 Fresenius Kabi Deutschland Gmbh Hydroxyalkyl starch derivatives as reactants for coupling to thiol groups
AU2014234272A1 (en) * 2013-03-20 2015-10-08 Fresenius Kabi Deutschland Gmbh Hydroxyalkyl starch derivatives as reactants for coupling to thiol groups
EP2976117B1 (de) 2013-03-22 2020-12-30 Amgen Inc. Injektor und verfahren zur montage
JP6520712B2 (ja) 2013-09-24 2019-05-29 味の素株式会社 糖アミノ酸およびその用途
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3060275B1 (de) 2013-10-24 2019-07-03 Amgen Inc. Injektor und verfahren zur montage
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
JP2017512133A (ja) * 2014-02-10 2017-05-18 ハネウェル・インターナショナル・インコーポレーテッド 液相フッ素化のための反応器デザイン
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
EP3785749B1 (de) 2014-05-07 2026-04-01 Amgen Inc. Autoinjektor mit stossabsorbierenden elementen
EP4036924A1 (de) 2014-06-03 2022-08-03 Amgen, Inc Vorrichtungen und verfahren zur unterstützung eines benutzers einer arzneimittelabgabevorrichtung
CN104072608A (zh) * 2014-06-23 2014-10-01 山东齐都药业有限公司 含羧基羟乙基淀粉衍生物修饰的牛血清白蛋白偶联物及其制备方法
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
EP3689394A1 (de) 2014-12-19 2020-08-05 Amgen Inc. Arzneimittelabgabevorrichtung mit live-knopf oder benutzerschnittstellenfeld
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (de) 2015-02-27 2022-04-13 Amgen, Inc Arzneimittelabgabevorrichtung mit nadelschutzmechanismus mit abstimmbarem widerstandsschwellwert gegenüber der bewegung des nadelschutzes
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
EP3721922B1 (de) 2016-03-15 2022-05-04 Amgen Inc. Verringerung der wahrscheinlichkeit auf glasbruch in arzneimittelabgabevorrichtungen
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
KR20190012189A (ko) 2016-05-20 2019-02-08 옥타파마 아게 약동학이 개선된 글리코실화 vwf 융합 단백질
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
CA3049780A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
JP7280189B2 (ja) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド 薬物送達装置用の挿入機構
EP3582825A1 (de) 2017-02-17 2019-12-25 Amgen Inc. Wirkstofffreisetzungsvorrichtung mit steriler fluidströmung und zugehöriges verfahren zur montage
MX2019010544A (es) 2017-03-06 2019-10-21 Amgen Inc Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
KR102893480B1 (ko) 2017-03-09 2025-11-28 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
JP2020511499A (ja) 2017-03-20 2020-04-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
BR112019020053B1 (pt) 2017-03-28 2023-10-10 Amgen Inc Máquina para acoplar uma haste de êmbolo a um conjunto de seringa e método de utilização da referida máquina
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
AU2018290302B2 (en) 2017-06-23 2024-02-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP4292576A3 (de) 2017-07-21 2024-01-17 Amgen Inc. Gasdurchlässiges dichtungselement für arzneimittelbehälter und verfahren zur montage
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
EP3664863A2 (de) 2017-08-09 2020-06-17 Amgen Inc. Hydraulisch-pneumatisches druckkammer-arzneimittelabgabesystem
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP4257164A3 (de) 2017-10-06 2024-01-17 Amgen Inc. Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
EP3703779B1 (de) 2017-11-03 2026-01-28 Amgen Inc. Systeme und vorgehen zur sterilisation einer arzneimittelabgabevorrichtung
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
IL273637B2 (en) 2017-11-10 2025-09-01 Amgen Inc Pistons for drug delivery devices
CN111263651B (zh) 2017-11-16 2022-06-17 安进公司 具有停顿和终点检测的自动注射器
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
CN108403641B (zh) * 2018-02-08 2020-03-20 华中科技大学 一种载药纳米材料及其制备方法
CN108503718B (zh) * 2018-02-08 2020-03-20 华中科技大学 一种羟烷基淀粉偶联物及其制备方法和应用
CN108219019B (zh) * 2018-02-08 2020-03-20 华中科技大学 一种巯基化羟乙基淀粉及其修饰的纳米材料和制备方法
WO2019212377A1 (ru) * 2018-05-04 2019-11-07 Farber Boris Slavinovich Фармацевтическая композиция на основе полимиксина для лечения инфекционных заболеваний
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
JP2022500095A (ja) 2018-09-24 2022-01-04 アムジエン・インコーポレーテツド インターベンション投薬システム及び方法
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
MA53815A (fr) 2018-10-02 2022-01-05 Amgen Inc Systèmes d'injection pour administration de médicament avec transmission de force interne
AU2019355979B2 (en) 2018-10-05 2024-12-05 Amgen Inc. Drug delivery device having dose indicator
JP7719714B2 (ja) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
TWI846741B (zh) 2018-10-15 2024-07-01 美商安進公司 用於藥物遞送裝置之平台組裝方法
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
ES3010833T3 (en) 2018-11-01 2025-04-04 Amgen Inc Drug delivery devices with partial drug delivery member retraction
CA3113076A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
CN111157736A (zh) * 2018-11-08 2020-05-15 中国科学院大连化学物理研究所 一种基于化学酶促的人血清o糖基化鉴定方法
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
KR20250099137A (ko) 2022-11-02 2025-07-01 에프. 호프만-라 로슈 아게 당단백질 조성물의 생산 방법
AR131133A1 (es) 2023-05-24 2025-02-19 Ambrx Inc INTERFERÓN l BOVINO PEGILADO Y MÉTODOS DE USO DEL MISMO
WO2025262329A1 (en) 2024-06-21 2025-12-26 Syntab Therapeutics Gmbh Synthetic molecules comprising tlr2 ligands
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (de)
US3191291A (en) 1959-01-21 1965-06-29 Continental Can Co Art of producing very thin steel and like sheets in wide strips
NL269801A (nl) 1960-10-04 1964-03-10 Farbwerke Höchst Ag Werkwijze ter bereiding van in water onoplosbare kleurstoffen
GB1385403A (en) 1971-07-14 1975-02-26 Unilever Ltd Process for preparing oxidised carbohydrates
GB1419080A (en) 1972-12-29 1975-12-24 Cheminova As Chemical compounds having juvenile hormone activity
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4125492A (en) * 1974-05-31 1978-11-14 Pedro Cuatrecasas Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers
US4001401A (en) 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) * 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
FR2378094A2 (fr) 1977-01-24 1978-08-18 Inst Nat Sante Rech Med Nouveaux reactifs biologiques constitues par des supports solides sur lesquels sont couples des composes organiques comportant un residu glucidique
EP0019403B1 (de) * 1979-05-10 1985-07-31 American Hospital Supply Corporation Arzneimittelträger auf der Basis von Hydroxyalkyl-Stärke
DE3029307A1 (de) * 1980-08-01 1982-03-04 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Haemoglobin enthaltendes blutersatzmittel
US4454161A (en) 1981-02-07 1984-06-12 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process for the production of branching enzyme, and a method for improving the qualities of food products therewith
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
FI82266C (fi) 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
EP0127839B1 (de) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Verfahren zur Herstellung eines rekombinanten Baculovirus-Expressionsvektors
LU85582A1 (fr) 1983-10-11 1985-06-04 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique,procedes pour leur preparation et compositions pharmaceutiques les contenant
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
SK46598A3 (en) * 1985-01-03 2000-05-16 Genetics Inst Recombinant dna plasmid vector, mammalian cell transformed with this vector, recombinant human erythropoietin, and method of its production
DE3501616A1 (de) 1985-01-17 1986-07-17 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von hydroxylamin-derivaten
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5217998A (en) * 1985-07-02 1993-06-08 Biomedical Frontiers, Inc. Composition for the stabilization of deferoxamine to chelate free ions in physiological fluid
US4863964A (en) 1985-07-02 1989-09-05 Biomedical Frontiers, Inc. Method for the stabilization of deferoxamine to chelate free ions in physiological fluid
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
IT1203814B (it) 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
FR2600894B1 (fr) 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JP2594123B2 (ja) 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
EP0307827A3 (de) 1987-09-15 1989-12-27 Kuraray Co., Ltd. Makromolekulare Komplexe, ihre Herstellung und Verwendung in der Medizin
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DK110188D0 (da) 1988-03-02 1988-03-02 Claus Selch Larsen High molecular weight prodrug derivatives of antiinflammatory drugs
FR2630329B1 (fr) 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
IT1219942B (it) 1988-05-13 1990-05-24 Fidia Farmaceutici Esteri polisaccaridici
US4900780A (en) 1988-05-25 1990-02-13 Masonic Medical Research Laboratory Acellular resuscitative fluid
US4925677A (en) 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5420105A (en) 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
DE3836600A1 (de) 1988-10-27 1990-05-03 Wolff Walsrode Ag Kohlensaeureester von polysacchariden und verfahren zu ihrer herstellung
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US6261800B1 (en) 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
DE19975071I2 (de) 1989-06-16 2000-02-03 Fresenius Ag Hydroxyethylstaerke als Plasmaexpander Verfahren zu ihrer Herstellung und Verwendung als kolloidales Plasmaersatzmittel
JP2896580B2 (ja) 1989-08-25 1999-05-31 チッソ株式会社 アミロース―リゾチームハイブリッドと活性化糖およびその製造法
JP2838800B2 (ja) 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
JP2975632B2 (ja) 1990-03-30 1999-11-10 生化学工業株式会社 グリコサミノグリカン修飾プロテイン
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
DK130991D0 (da) * 1991-07-04 1991-07-04 Immunodex K S Polymere konjugater
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
DE4130807A1 (de) 1991-09-17 1993-03-18 Wolff Walsrode Ag Verfahren zur herstellung von polysaccharidcarbonaten
US6172208B1 (en) 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
AU5098193A (en) * 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
GB2270920B (en) 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
FI935485L (fi) 1992-12-09 1994-06-10 Ortho Pharma Corp PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset
CA2110543A1 (en) 1992-12-09 1994-06-10 David E. Wright Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
DE69401109T2 (de) 1993-03-16 1997-05-28 Hemosol Inc Selektive vernetzung von hemoglobin mittels oxidierten, ringgeöffneten sacchariden
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
JPH07188291A (ja) 1993-12-27 1995-07-25 Hayashibara Biochem Lab Inc 蛋白質とその製造方法並びに用途
US5876980A (en) 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US6214331B1 (en) 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
US5981507A (en) 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
US5723589A (en) 1995-12-21 1998-03-03 Icn Pharmaceuticals Carbohydrate conjugated bio-active compounds
DE69735057T2 (de) 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
US5696152A (en) 1996-05-07 1997-12-09 Wisconsin Alumni Research Foundation Taxol composition for use as organ preservation and cardioplegic agents
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
DE19628705A1 (de) * 1996-07-08 1998-01-15 Fresenius Ag Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5851984A (en) 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6011008A (en) 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
US5952347A (en) 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
DE69835308T2 (de) * 1997-08-07 2007-08-09 University Of Utah Research Foundation, Salt Lake City Prodrugs und Konjugate von Selenoenthaltenden Verbindungen und ihre Verwendung
US5847110A (en) 1997-08-15 1998-12-08 Biomedical Frontiers, Inc. Method of reducing a schiff base
US6875594B2 (en) 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
NZ505651A (en) * 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
DE19808079A1 (de) 1998-02-20 1999-08-26 Schering Ag Hydroxyethylstärke-Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
DE69909987T2 (de) 1998-03-05 2004-05-27 Asahi Glass Co., Ltd. Sputtertarget, transparenter leitender film und verfahren zu dessen herstellung
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6261594B1 (en) 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
EP1035137A1 (de) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Verfahren zur reduktiven aminierung von polysacchariden
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US7279176B1 (en) 1999-09-02 2007-10-09 Rice University Nitric oxide-producing hydrogel materials
US20020065410A1 (en) 1999-12-02 2002-05-30 Antrim Richard L. Branched starches and branched starch hydrolyzates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP2001294601A (ja) 2000-04-11 2001-10-23 Akita Prefecture 高度分岐澱粉と該高度分岐澱粉の製造方法
JP2002003398A (ja) 2000-04-17 2002-01-09 Ltt Institute Co Ltd 徐放製剤、その製造法及びワクチン
DE10023051B4 (de) * 2000-05-11 2004-02-19 Roche Diagnostics Gmbh Verfahren zur Herstellung von Fluoresceinisothiocyanat-Sinistrin, dessen Verwendung und Fluoresceinisothiocyanat-Sinistrin enthaltende diagnostische Zubereitung
FR2811967B1 (fr) 2000-07-24 2002-12-13 Cebal Tube muni d'une tete de fixation pour divers bouchages et les divers bouchages munis de moyens de fixation sur ledit tube
US6417347B1 (en) 2000-08-24 2002-07-09 Scimed Life Systems, Inc. High yield S-nitrosylation process
DE10041541A1 (de) 2000-08-24 2002-03-14 Michael Duchene Rekombinante Allergene aus der Motte Plodia interpunctella
AU2001273388B2 (en) 2000-09-08 2005-01-13 Gryphon Therapeutics, Inc. "Pseudo"-native chemical ligation
DE10105921A1 (de) 2001-02-09 2002-08-14 Braun Melsungen Ag An Kolloide gebundene Arzneiwirkstoffe
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10126158A1 (de) 2001-05-30 2002-12-12 Novira Chem Gmbh Eine Methode zur Synthese von Gemischen einfach aktivierter und nicht aktivierter Polyoxyalkylene zur Modifizierung von Proteinen
DE10129369C1 (de) 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats
DE10135694A1 (de) 2001-07-21 2003-02-06 Supramol Parenteral Colloids Amphiphile Stärke-und Hydroxyethylstärke-Konjugate
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7629456B2 (en) 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
US6375846B1 (en) 2001-11-01 2002-04-23 Harry Wellington Jarrett Cyanogen bromide-activation of hydroxyls on silica for high pressure affinity chromatography
DE10155098A1 (de) 2001-11-09 2003-05-22 Supramol Parenteral Colloids Mittel zur Prävention von mykotischen Kontaminationen bei der Zell- und Gewebekultur bakteriellen, pflanzlichen, animalischen und humanen Ursprungs, bestehend aus Polyen-Makrolid-Konjugaten mit Polysacchariden
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
DE10207072A1 (de) * 2002-02-20 2003-08-28 Supramol Parenteral Colloids Stärkederivate, ihre Konjugate und Verfahren zur Herstellung derselben
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
EP1496076B1 (de) 2002-03-13 2007-07-25 Beijing Jiankai Technology Co., Ltd. Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff
DE10217994A1 (de) 2002-04-23 2003-11-06 Supramol Parenteral Colloids Konjugate von hyperverzweigten Polysacchariden
WO2003102018A2 (en) 2002-06-03 2003-12-11 The Institute For Systems Biology Methods for quantitative proteome analysis of glycoproteins
US20040101546A1 (en) 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
EP1591467A1 (de) 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Konjugat aus einem Polyethylene Glykol mit einer Alkanal Endgruppe und einem menschlichen Wachstumshormon
ES2897470T3 (es) 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
DE10242076A1 (de) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
DE02020425T1 (de) 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
AU2003260393B2 (en) 2002-09-11 2009-10-01 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
DE60323756D1 (de) 2002-10-08 2008-11-06 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
DE10254745A1 (de) 2002-11-23 2004-06-03 Supramol Parenteral Colloids Gmbh Imidazolide von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
DE10256558A1 (de) 2002-12-04 2004-09-16 Supramol Parenteral Colloids Gmbh Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
KR101154343B1 (ko) 2003-08-08 2012-07-05 프레제니우스 카비 도이치란트 게엠베하 히드록시알킬 스타치 및 ｇ-ｃｓｆ의 컨쥬게이트
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
HRP20110056T1 (hr) 2003-08-08 2011-02-28 Fresenius Kabi Deutschland Gmbh Konjugati hidroksialkil škroba i g-csf
US20080206182A1 (en) 2003-08-08 2008-08-28 Fresenius Kabi Deutschland Gmbh Conjugates of a Polymer and a Protein Linked by an Oxime Group
CA2556169C (en) 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
DE102004009783A1 (de) 2004-02-28 2005-09-15 Supramol Parenteral Colloids Gmbh Hyperverzweigte Stärkefraktion, Verfahren zu ihrer Herstellung und ihre Konjugate mit pharmazeutischen Wirkstoffen
EP1758608A2 (de) 2004-03-11 2007-03-07 Fresenius Kabi Deutschland GmbH Konjugate von hydroxyalkylstärke und erythropoetin
AR048035A1 (es) 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
EP2279752A3 (de) 2004-03-11 2011-08-24 Fresenius Kabi Deutschland GmbH Konjugate von hydroxyalkylstärke und einem protein hergestellt durch native chemische ligation
US20050265958A1 (en) 2004-05-14 2005-12-01 West Jennifer L Nitric oxide releasing compositions and associated methods
EP1861124A2 (de) 2005-03-11 2007-12-05 Fresenius Kabi Deutschland GmbH Herstellung von bioaktiven glykoproteinen aus inaktiven ausgangsmaterialien durch konjugation mit hydroxyalkylstärke
EP1762250A1 (de) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
EP1942942A2 (de) 2005-10-31 2008-07-16 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Von polysaccharid stammende stickoxid-freisetzende kohlenstoffgebundene diazeniumdiolate
JP2009093397A (ja) 2007-10-09 2009-04-30 Panasonic Corp タッチパネル及びこれを用いた入力装置
EP2070951A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Verfahren zur Herstellung eines Hydroxyalkylstärkederivats mit zwei Linkern
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
JP2012505228A (ja) 2008-10-07 2012-03-01 レクサン ファーマシューティカルズ インコーポレイテッド Ｈｐｍａ−ドセタキセルまたはゲムシタビンコンジュゲートおよびその使用

Also Published As

Publication number Publication date
BR0314106A (pt) 2005-07-19
EP2272865A2 (de) 2011-01-12
AU2009238372A1 (en) 2009-12-17
MXPA05002593A (es) 2005-05-27
EP2143736B1 (de) 2012-11-07
MXPA05002594A (es) 2005-05-27
KR101174510B1 (ko) 2012-08-16
JP2010265464A (ja) 2010-11-25
MX2010006175A (es) 2010-07-05
DK1398327T3 (da) 2008-11-10
JP2011089125A (ja) 2011-05-06
EP2154160A1 (de) 2010-02-17
RU2005110415A (ru) 2006-08-27
PT1398327E (pt) 2008-10-31
DK1398322T3 (da) 2006-08-21
EP1398322B1 (de) 2006-04-19
AU2003260393A1 (en) 2004-04-30
EP1398328B1 (de) 2009-11-18
CY1109813T1 (el) 2014-09-10
AU2003255406B2 (en) 2009-09-10
PL217085B1 (pl) 2014-06-30
RU2326891C2 (ru) 2008-06-20
EP2017287A2 (de) 2009-01-21
DE60330098D1 (de) 2009-12-31
AU2003255406A1 (en) 2004-04-30
PL375037A1 (en) 2005-11-14
ES2213507T3 (es) 2010-04-15
KR101045401B1 (ko) 2011-06-30
PT1398328E (pt) 2010-02-19
ATE323723T1 (de) 2006-05-15
US20050238723A1 (en) 2005-10-27
DE03020425T1 (de) 2004-07-15
ES2213507T1 (es) 2004-09-01
ES2213505T3 (es) 2006-11-16
RU2328505C2 (ru) 2008-07-10
AU2003253399A1 (en) 2004-04-30
WO2004024761A1 (en) 2004-03-25
PL374969A1 (en) 2005-11-14
US20120046240A9 (en) 2012-02-23
DE60304640T2 (de) 2007-05-16
CA2496317C (en) 2014-02-18
JP5275293B2 (ja) 2013-08-28
HK1063478A1 (en) 2004-12-31
EP2143736A1 (de) 2010-01-13
SI1398328T1 (sl) 2010-02-26
US8475765B2 (en) 2013-07-02
AR045234A1 (es) 2005-10-19
TW200418875A (en) 2004-10-01
AR045235A1 (es) 2005-10-19
AU2011200219B2 (en) 2012-05-17
US20100317609A1 (en) 2010-12-16
HK1136226A1 (en) 2010-06-25
AU2003260393B2 (en) 2009-10-01
DE60304640D1 (de) 2006-05-24
IL166506A0 (en) 2006-01-15
PL216545B1 (pl) 2014-04-30
DK1398328T3 (da) 2010-03-08
NO20051427L (no) 2005-05-31
KR101045422B1 (ko) 2011-06-30
EP2316850A2 (de) 2011-05-04
WO2004024777A8 (en) 2005-03-24
EP2316850A3 (de) 2011-11-09
CN1681844A (zh) 2005-10-12
IL166506A (en) 2010-02-17
BR0314227A (pt) 2005-10-25
US8618266B2 (en) 2013-12-31
NO20051419L (no) 2005-05-30
ES2213505T1 (es) 2004-09-01
AU2011200158A1 (en) 2011-02-03
CN1681846A (zh) 2005-10-12
AR041097A1 (es) 2005-05-04
KR20050061466A (ko) 2005-06-22
DE03020423T1 (de) 2004-07-15
RU2005110412A (ru) 2006-01-20
ES2213506T3 (es) 2009-02-16
ZA200600651B (en) 2007-04-25
WO2004024776A1 (en) 2004-03-25
AU2009238372B2 (en) 2012-08-23
EP2272865A3 (de) 2014-06-18
EP1398322A1 (de) 2004-03-17
ATE449112T1 (de) 2009-12-15
KR20050072417A (ko) 2005-07-11
JP5455821B2 (ja) 2014-03-26
MXPA05002591A (es) 2005-09-20
US20060019877A1 (en) 2006-01-26
IL200150A0 (en) 2011-07-31
CA2495242A1 (en) 2004-03-25
DE20321836U1 (de) 2011-04-07
EP1398327A1 (de) 2004-03-17
AU2011200219A1 (en) 2011-02-10
IL166931A (en) 2012-06-28
JP2010248528A (ja) 2010-11-04
US20050234230A1 (en) 2005-10-20
DE60323192D1 (de) 2008-10-09
RU2005110423A (ru) 2006-01-20
EP1398327B1 (de) 2008-08-27
US20110054152A1 (en) 2011-03-03
BR0314107A (pt) 2005-07-19
RU2329274C2 (ru) 2008-07-20
ES2399006T3 (es) 2013-03-25
ES2213506T1 (es) 2004-09-01
SI1398327T1 (sl) 2009-02-28
IL166930A (en) 2012-08-30
EP2017287A3 (de) 2009-11-04
KR20050075336A (ko) 2005-07-20
EP1398328A1 (de) 2004-03-17
WO2004024777A1 (en) 2004-03-25
CA2496317A1 (en) 2004-03-25
DE03020424T1 (de) 2004-07-15
AU2011200158B2 (en) 2012-08-02
JP2006516534A (ja) 2006-07-06
HK1063475A1 (en) 2004-12-31
HK1063477A1 (en) 2004-12-31
US7815893B2 (en) 2010-10-19
CN100348618C (zh) 2007-11-14
PT1398322E (pt) 2006-08-31
AU2003253399B2 (en) 2010-10-14
PL374490A1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
ATE406387T1 (de) Verfahren zur herstellung von hydroxyalkylstärkederivaten
ATE386736T1 (de) Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
DE60221399D1 (de) Verfahren zur herstellung von mitteldistillaten
ATE403641T1 (de) Verfahren zur herstellung von o- desmethylvenlafaxin
ATE414077T1 (de) Verfahren zur herstellung von 1-ä(benzimidazol-1- yl)chinolin-8-ylüpiperidin-4-ylaminderivaten
DE60324720D1 (de) Verfahren zur Herstellung dekorativer Gegenstände
DE60230908D1 (de) Verfahren zur herstellung von polyarylenethern
DE60317690D1 (de) Verfahren zur herstellung von valsartan
ATE286011T1 (de) Verfahren zur herstellung von 1-octen
DE50308650D1 (de) Verfahren zur herstellung von cellulosecarbamatformkörpern
ATE448209T1 (de) Verfahren zur herstellung von pyrimidinverbindungen
ATE456569T1 (de) Verfahren zur herstellung von 6-alkyliden- penemderivaten
ATE376997T1 (de) Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
ATE441662T1 (de) Verfahren zur herstellung von echinocandinderivaten
ATE284875T1 (de) Verfahren zur herstellung von mesylaten von piperazinderivaten
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
DE50200870D1 (de) Verfahren zur herstellung von hydroxyalkylpolysiloxanen
ATE374757T1 (de) Verfahren zur herstellung von (1,4,5)- oxadiazepinderivaten
ATE402138T1 (de) Verfahren zur herstellung von 2- aminoindanderivaten
ATE371642T1 (de) Verfahren zur herstellung von 3- methylthiopropanal
ATE382621T1 (de) Verfahren zur herstellung von nevirapin
ATE471941T1 (de) Verfahren zur herstellung von thiazolopyrimidinen
ATE294166T1 (de) Verfahren zur herstellung von thiazolderivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1398327

Country of ref document: EP